BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Glioblastoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Glioblastoma\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04881032-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT04881032)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: AGuIX Nanopart
 icles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of 
 Newly Diagnosed Glioblastoma\nEstimated primary completion: November 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04881032
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06160206-2008@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06160206)
DESCRIPTION:Bevacizumab\, phase 2\, Recurrent Glioblastoma.\nStudy: Retifan
 limab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment
  of Recurrent Glioblastoma\nEstimated primary completion: 30 November 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06160206
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04019262-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT04019262)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Short Course C
 hemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma\nEst
 imated primary completion: December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04019262
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04478279-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT04478279)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: A Phase 1-2 St
 udy of ST101 in Patients With Advanced Solid Tumors\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04478279
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05664243-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT05664243)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: A Phase 1b / 2
  Drug Resistant Immunotherapy With Activated\, Gene Modified Allogeneic or
  Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolo
 mide in Subjects With Recurrent or Newly Diagnosed Glioblastoma\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05664243
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06258018-2052@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Niraparib: Phase 1/2 readout est. (NCT06258018)
DESCRIPTION:Niraparib\, phase 1/2\, Glioblastoma.\nStudy: Niraparib and Tem
 ozolomide in Patients Glioblastoma\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06258018
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06258018-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06258018)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Niraparib and 
 Temozolomide in Patients Glioblastoma\nEstimated primary completion: Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 258018
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03643549-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT03643549)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Bortezomib and
  Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORT
 EM-17)\nEstimated primary completion: 30 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03643549
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04623931-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT04623931)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Chemotherapy and
  Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histol
 ogical (Molecular) Glioblastomas\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0462
 3931
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06649851-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06649851)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: G-CSF After Chem
 o-radiation in Patients With Glioblastoma\nEstimated primary completion: 3
 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temoz
 olomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06649851
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01837862-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT01837862)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: A Phase I Stud
 y of Mebendazole for the Treatment of Pediatric Gliomas\nEstimated primary
  completion: March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT01837862
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06810544-2771@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:TNG456: Phase 1/2 readout est. (NCT06810544)
DESCRIPTION:TNG456\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Safety
  and Tolerability of TNG456 Alone and in Combination With Abemaciclib in P
 atients With Solid Tumors With MTAP Loss\nEstimated primary completion: 31
  March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tng456#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06810
 544
URL:https://assetmemo.bio/drug/tng456#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03688178-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Temozolomide: Phase 2 readout est. (NCT03688178)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: DC Migration Stu
 dy to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab\
 nEstimated primary completion: 31 March 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03688178
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07193654-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07193654)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Stupp Treatment 
 With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spre
 ad\nEstimated primary completion: 1 April 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07193654
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05271240-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Temozolomide: Phase 3 readout est. (NCT05271240)
DESCRIPTION:Temozolomide\, phase 3\, Glioblastoma.\nStudy: Repeated Superse
 lective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozo
 lomide and Radiation Compared to Temozolomide and Radiation Alone in Newly
  Diagnosed GBM\nEstimated primary completion: 1 April 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05271240
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03663725-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Temozolomide: Phase 3 readout est. (NCT03663725)
DESCRIPTION:Temozolomide\, phase 3\, Glioblastoma.\nStudy: Treatment Intens
 ification With Temozolomide in Adults With a Glioblastoma\nEstimated prima
 ry completion: June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03663725
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03862430-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Temozolomide: Phase 2 readout est. (NCT03862430)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: A Study of NanO2
 ™ Combined With Radiation and Temozolomide in Patients With Newly Diagno
 sed GBM\nEstimated primary completion: 30 June 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03862430
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02649582-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT02649582)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Adjuvant Dendr
 itic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients\nEstima
 ted primary completion: July 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/temozolomide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT02649582
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04116411-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270916
DTEND;VALUE=DATE:20270917
SUMMARY:Temozolomide: Phase 2 readout est. (NCT04116411)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: A Clinical Trial
  Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients\nEstim
 ated primary completion: 16 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04116411
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07476794-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07476794)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Daily Temozolomi
 de for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed G
 liOblatoma\nEstimated primary completion: October 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07476794
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05629702-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20271007
DTEND;VALUE=DATE:20271008
SUMMARY:Temozolomide: Phase 2 readout est. (NCT05629702)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: ARISTOCRAT: Blin
 ded Trial of Temozolomide +/- Cannabinoids\nEstimated primary completion: 
 7 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temoz
 olomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05629702
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06297512-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20271109
DTEND;VALUE=DATE:20271110
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06297512)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Evaluate the Rol
 e of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM
 ).\nEstimated primary completion: 9 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06297512
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225621-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07225621)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Adjuvant Temozol
 omide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodyna
 mic Therapy System for Newly Diagnosed Glioblastoma\nEstimated primary com
 pletion: December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07225621
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06388733-2052@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Niraparib: Phase 3 readout est. (NCT06388733)
DESCRIPTION:Niraparib\, phase 3\, Glioblastoma.\nStudy: A Study Comparing N
 iraparib With Temozolomide in Adult Participants With Newly-diagnosed\, MG
 MT Unmethylated Glioblastoma\nEstimated primary completion: December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/niraparib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06388733
URL:https://assetmemo.bio/drug/niraparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670026-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07670026)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Intensified Adju
 vant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Rese
 ction or Short-Term Progression\nEstimated primary completion: 1 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076700
 26
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03491683-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT03491683)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: INO-5401 and I
 NO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (
 REGN2810) in Newly-Diagnosed Glioblastoma (GBM)\nEstimated primary complet
 ion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03491683
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02344355-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT02344355)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: A Phase 2 Trial 
 of High-Dose Ascorbate in Glioblastoma Multiforme\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT02344355
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297212-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07297212)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: A Clinical Trial
  Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How
  Well it Works in Patients With Recurrent Glioblastoma\nEstimated primary 
 completion: January 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07297212
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07707973-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280103
DTEND;VALUE=DATE:20280104
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07707973)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Nimotuzumab Comb
 ined With the Stupp Regimen for Postoperative Residual Glioblastoma\nEstim
 ated primary completion: 3 January 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07707973
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06504381-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06504381)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: DB107-RRV\, DB
 107-FC\, and Radiation Therapy With or Without Temozolomide (TMZ) for High
  Grade Glioma\nEstimated primary completion: 31 January 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06504381
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07263438-2008@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07263438)
DESCRIPTION:Bevacizumab\, phase 2\, Recurrent Glioblastoma.\nStudy: Efficac
 y of the Combination of Trimipramine and Atezolizumab With Bevacizumab in 
 Patients With Recurrent Glioblastoma: a Phase 2 Trial\nEstimated primary c
 ompletion: 30 March 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07263438
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04945148-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Temozolomide: Phase 2 readout est. (NCT04945148)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Oxidative Phosph
 orylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy 
 Temozolomide\nEstimated primary completion: May 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04945148
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06012695-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06012695)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: NBM-BMX Admini
 stered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastom
 a\nEstimated primary completion: 30 May 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06012695
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03213002-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT03213002)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Oral Capecitab
 ine and Temozolomide (CAPTEM) for Newly Diagnosed GBM\nEstimated primary c
 ompletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03213002
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03970447-2373@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:AZD1390: Phase 2/3 readout est. (NCT03970447)
DESCRIPTION:AZD1390\, phase 2/3\, Glioblastoma.\nStudy: A Trial to Evaluate
  Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma\nEstimate
 d primary completion: June 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/azd1390#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03970447
URL:https://assetmemo.bio/drug/azd1390#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05765812-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT05765812)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: A Study of Zed
 oresertib (Debio 0123) in Combination With Temozolomide in Adult Participa
 nts With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 
 0123) in Combination With Temozolomide and Radiotherapy in Adult Participa
 nts With Newly Diagnosed Glioblastoma\nEstimated primary completion: Septe
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5765812
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05765812-9091@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Zedoresertib: Phase 1/2 readout est. (NCT05765812)
DESCRIPTION:Zedoresertib\, phase 1/2\, Glioblastoma.\nStudy: A Study of Zed
 oresertib (Debio 0123) in Combination With Temozolomide in Adult Participa
 nts With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 
 0123) in Combination With Temozolomide and Radiotherapy in Adult Participa
 nts With Newly Diagnosed Glioblastoma\nEstimated primary completion: Septe
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zedoresert
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5765812
URL:https://assetmemo.bio/drug/zedoresertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07439172-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07439172)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Pre-Radiation Ch
 emotherapy for Newly Diagnosed High-Grade Glioma.\nEstimated primary compl
 etion: September 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07439172
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07326566-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07326566)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Study of Silever
 tinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unme
 thylated MGMT and EGFRvIII\nEstimated primary completion: November 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07326566
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365280-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20281224
DTEND;VALUE=DATE:20281225
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07365280)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Neoantigen-Pulse
 d Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly D
 iagnosed Glioblastoma\nEstimated primary completion: 24 December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07365280
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05439278-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Temozolomide: Phase 3 readout est. (NCT05439278)
DESCRIPTION:Temozolomide\, phase 3\, Glioblastoma.\nStudy: Conventional Ver
 sus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastom
 a\nEstimated primary completion: 31 December 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05439278
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01777919-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Temozolomide: Phase 2 readout est. (NCT01777919)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Disulfiram/Coppe
 r Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform\n
 Estimated primary completion: January 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT01777919
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07347210-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07347210)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Evaluation of UC
 PVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvan
 t Therapy in Patients With Unmethylated MGMT Glioblastoma\nEstimated prima
 ry completion: January 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/temozolomide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07347210
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391215-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290119
DTEND;VALUE=DATE:20290120
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07391215)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: 5G-PEARL: Paxa
 lisib in Malignant Brain Tumours\nEstimated primary completion: 19 January
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07391
 215
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07754734-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07754734)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: STUPP Regimen Wi
 th or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promot
 er Methylation\nEstimated primary completion: 31 July 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07754734
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07758062-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07758062)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Levetiracetam Ex
 tended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma\n
 Estimated primary completion: 1 August 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07758062
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05843253-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Temozolomide: Phase 2 readout est. (NCT05843253)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Study of Ribocic
 lib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG\,
  H3G34-mutant\nEstimated primary completion: 31 August 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05843253
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06630260-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT06630260)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: 5G-RUBY: Avuto
 metinib and Defactinib in Malignant Brain Tumours\nEstimated primary compl
 etion: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06630260
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07569042-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07569042)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: A Rollover Stu
 dy of NBM-BMX in Combination With Temozolomide in Patients With Newly Diag
 nosed Glioblastoma\nEstimated primary completion: 30 September 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07569042
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605364-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Temozolomide: Phase 2/3 readout est. (NCT07605364)
DESCRIPTION:Temozolomide\, phase 2/3\, Glioblastoma.\nStudy: Testing the Ad
 dition of an Anti-Cancer Drug\, Mycophenolate Mofetil\, to the Usual Treat
 ment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer\nEstim
 ated primary completion: 30 September 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07605364
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06061809-2008@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06061809)
DESCRIPTION:Bevacizumab\, phase 2\, Recurrent Glioblastoma.\nStudy: N-803 a
 nd PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Gli
 oblastoma\nEstimated primary completion: 31 December 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06061809
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06805305-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06805305)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: DOC1021 Dendriti
 c Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (
 GBM)\nEstimated primary completion: March 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06805305
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859059-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07859059)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Metronomic Tem
 ozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblas
 toma\nEstimated primary completion: 1 June 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07859059
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04373785-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT04373785)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: NG101m Adjuvan
 t Therapy in Glioblastoma Patients\nEstimated primary completion: 30 July 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT043737
 85
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762716-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07762716)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Combination Im
 munotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment 
 (Designed and Manufactured Per Patient)\, Chemotherapy and Anti PD-1 Thera
 py\nEstimated primary completion: September 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07762716
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811297-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07811297)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: A Study of Cat
 equentinib Hydrochloride (AL3818) in Endometrial\, LGSOC\, STS or GBM Canc
 ers\nEstimated primary completion: 1 September 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07811297
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07873996-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20301015
DTEND;VALUE=DATE:20301016
SUMMARY:Temozolomide: Phase 2/3 readout est. (NCT07873996)
DESCRIPTION:Temozolomide\, phase 2/3\, Glioblastoma.\nStudy: Tris-CAR-T Cel
 l Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma\nEstima
 ted primary completion: 15 October 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07873996
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05685004-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Temozolomide: Phase 2/3 readout est. (NCT05685004)
DESCRIPTION:Temozolomide\, phase 2/3\, Glioblastoma.\nStudy: Study of Neoan
 tigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative G
 lioblastoma Multiforme (GBM)\nEstimated primary completion: November 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05685004
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06991101-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Temozolomide: Phase 2 readout est. (NCT06991101)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Ruxolitinib With
  Radiation and Temozolomide Compared to Radiation and Temozolomide for New
 ly Diagnosed Glioblastoma\nEstimated primary completion: December 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06991101
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04765514-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Temozolomide: Phase 2 readout est. (NCT04765514)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Chemoradiotherap
 y Versus Chemotherapy for Elderly and Frail GBM Patients\nEstimated primar
 y completion: June 2032. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04765514
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389278-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Temozolomide: Phase 1/2 readout est. (NCT07389278)
DESCRIPTION:Temozolomide\, phase 1/2\, Glioblastoma.\nStudy: Combination AD
 I-PEG 20\, TMZ\, and RT for Treatment of Newly Diagnosed High-grade Glioma
  (HGG)\nEstimated primary completion: 30 June 2032. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07389278
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06477939-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Temozolomide: Phase 3 readout est. (NCT06477939)
DESCRIPTION:Temozolomide\, phase 3\, Glioblastoma.\nStudy: Study of Adding 
 or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Ra
 diation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Pat
 ients\nEstimated primary completion: 31 December 2032. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06477939
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935889-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20351130
DTEND;VALUE=DATE:20351201
SUMMARY:Temozolomide: Phase 3 readout est. (NCT07935889)
DESCRIPTION:Temozolomide\, phase 3\, Glioblastoma.\nStudy: Advanced Imaging
 -Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatme
 nt of Newly Diagnosed Glioblastoma\, SAGA 2.0 Trial\nEstimated primary com
 pletion: 30 November 2035. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/temozolomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07935889
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07708961-8999@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20360831
DTEND;VALUE=DATE:20360901
SUMMARY:Temozolomide: Phase 2 readout est. (NCT07708961)
DESCRIPTION:Temozolomide\, phase 2\, Glioblastoma.\nStudy: Temozolomide\, W
 ith or Without WSD0922-FU\, for the Treatment of EGFR-Mutant\, IDH-Wildtyp
 e Glioblastoma\nEstimated primary completion: 31 August 2036. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/temozolomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07708961
URL:https://assetmemo.bio/drug/temozolomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
